We are pleased to announce the creation of a new scientific direction within DIXI medical. This direction will play a key role in the development of the company by ensuring that its activities are based on solid scientific foundations.

Appointment of John Gale as Chief Scientific Officer

‍To lead this new direction, John Gale has been promoted to Chief Scientific Officer. Formerly Vice President of DIXI NeuroLab, John brings a wealth of experience and recognized expertise in neuroscience.

An accomplished researcher, he has published numerous reference articles in prestigious journals, contributing to major advances in the understanding of neurodegenerative diseases and the development of new therapies. John Gale is an invaluable asset to the company, and his appointment testifies to DIXI medical’s commitment to scientific excellence and innovation.

Faical Isbaine joins as Director-Clinical Development

‍John will be supported by Faical Isbaine as Director-Clinical Development. Faical is an expert neurophysiologist, trained in the electrophysiology of neurodegenerative diseases in both France and the USA under the mentorship of John Gale.

Faical possesses extensive knowledge in imaging techniques. Prior to joining Dixi medical, he served as an intraoperative neurophysiologist and medical image analyst at Emory University, one of North America’s most prestigious neurosurgical centers. By joining hands with John Gale, they will ensure a state-of-the-art scientific approach to addressing technical challenges and innovations.

‍
Roles and Responsibilities of the Scientific Direction

‍The main mission of the scientific direction will be to guide the improvement of products, launch new products and projects, understand and evaluate new medical practices as well as new competitors. It will also provide support to DIXI medical’s commercial services in the preparation of their information and training work. In addition, it will act as a service unit for the Quality and Regulatory Affairs Department.

‍